Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial

COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved drug to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Elgohary, Mohamed Abdel-Salam, Hasan, Eman Medhat, Ibrahim, Amany Ahmad, Abdelsalam, Mohamed Farouk Ahmed, Abdel-Rahman, Raafat Zaher, Zaki, Ashraf Ibrahim, Elaatar, Mohamed Bakr, Elnagar, Mohamed Thabet, Emam, Mohamed Emam, Hamada, Mahmoud Moustafa, Abdel-Hamid, Taimour Mohamed, Abdel-Hafez, Ahmad Samir, Seadawy, Mohamed Gomaa, Fatoh, Ahmad Rashad, Elsaied, Mohamed Ali, Sakr, Marwa Abdel-Rahman, Elkady, Ahmed Omar, Shehata, Mohamed Muawad, Nawar, Osama Mohamed, Selem, Mohamed Abu-elnaga, Abd-aal, Mohamed Saeed, Lotfy, Hany Hafez, Elnagdy, Tarek Refaat, Helmy, Sherine, Mubark, Magdy Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015168/
https://www.ncbi.nlm.nih.gov/pubmed/35449996
http://dx.doi.org/10.25122/jml-2021-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015168/
https://www.ncbi.nlm.nih.gov/pubmed/35449996
http://dx.doi.org/10.25122/jml-2021-0175

Ejemplares similares